公开(公告)号：EP2352826A1

公开(公告)日：2011-08-10

申请号：EP09809520.1

申请日：2009-08-24

Applicant: Oncotherapy Science, Inc.

Inventor： NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

IPC: C12N15/09 ,  C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: The present invention relates to the roles played by OIP5 genes in lung and/or esophageal cancer carcinogenesis and features a method for treating and/or preventing lung and/or esophageal cancer by administering a double-stranded molecule against the OIP5 genes or a composition, vector or cell containing such a double-stranded molecule and antibody.The present invention also features methods for detecting and/or diagnosing lung and/or esophageal cancer, or assessing/determining the prognosis of and/or monitoring the efficacy of a cancer therapy in a patient with lung and/or esophageal cancer by detecting OIP5. Also, disclosed are methods of identifying compounds for treating and preventing cancer relating to OIP5.

公开(公告)号：EP2334789A1

公开(公告)日：2011-06-22

申请号：EP09809494.9

申请日：2009-08-13

Applicant: Oncotherapy Science, Inc.

Inventor： NAKAMURA, Yusuke ,  KATAGIRI, Toyomasa ,  TOGASHI, Akira

IPC: C12N15/09 ,  A61K31/7084 ,  A61K48/00 ,  A61P35/00 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/574

CPC classification number: G01N33/57415 ,  C12N15/113 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/57484 ,  G01N2333/4703 ,  G01N2500/04

Abstract: The present invention provides methods for detecting and diagnosing cancer, such methods involving the determination of the expression level of the RQCD1, GIGYF1 or GIGYF2 genes. These genes were discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer and methods for treating cancer. Moreover, the present invention provides siRNAs targeting the RQCD1, GIGYF1 and/or GIGYF2 genes, all of which are suggested to be useful in the treatment of cancer.

公开(公告)号：EP2321410A1

公开(公告)日：2011-05-18

申请号：EP09797719.3

申请日：2009-07-16

Applicant: Oncotherapy Science, Inc.

Inventor： NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

IPC: C12N15/09

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57423 ,  G01N2800/50

Abstract: The invention features methods for detecting lung cancer or esophageal cancer, by detecting over-expression of ECT2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing lung cancer or esophageal cancer, based on the over-expression of ECT2 in the lung cancer or esophageal cancer, the cell proliferation function of ECT2. Also, provided are a method for treating lung cancer or esophageal cancer by administering a double-stranded molecule against the ECT2 gene or an antibody against ECT2 protein. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods.

Abstract translation: 本发明的特征是检测肺癌或食管癌的方法，通过检测ECT2与正常器官相比过度表达。 还公开了鉴定用于治疗和预防肺癌或食管癌的化合物的方法，其基于ECT2在肺癌或食道癌中的过度表达，即ECT2的细胞增殖功能。 此外，提供了通过给予针对ECT2基因的双链分子或针对ECT2蛋白的抗体来治疗肺癌或食道癌的方法。 本发明还提供了产品，包括编码它们的双链分子和载体，以及包含该分子或载体的组合物，可用于所提供的方法中。

公开(公告)号：EP2313504A1

公开(公告)日：2011-04-27

申请号：EP09773163.2

申请日：2009-06-30

Applicant: Oncotherapy Science, Inc.

Inventor： TOGASHI, Akira ,  KATSU, Masakazu ,  TAKAYANAGI, Megumi ,  YOSHIOKA, Hiroki ,  NG, Pohsing ,  SHIBA, Yasuhiro ,  NAKAMURA, Yusuke ,  ENDO, Keigo

IPC: C12N15/09 ,  A61K39/395 ,  A61P35/00 ,  C07K16/18 ,  G01N33/574

CPC classification number: G01N33/57407 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/56 ,  C07K2317/565 ,  G01N2333/705

Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

公开(公告)号：EP2176406A1

公开(公告)日：2010-04-21

申请号：EP08776735.6

申请日：2008-06-26

Applicant: Oncotherapy Science, Inc.

Inventor： TOGASHI, Akira ,  TOBITA, Ryutaro ,  ISHIZAKI, Yuka ,  KONUMA, Akiko

IPC: C12N15/00 ,  A61K31/7105 ,  A61K48/00 ,  A61P35/00

CPC classification number: C12N15/113 ,  C12N2310/14

Abstract: The invention features a method for treating cancer by administering a double-stranded nucleic acid molecule against a CX gene selected from the group consisting of C14orf78, MYBL2, UBE2S and UBE2T. The invention also features products, including the double-stranded nucleic acid molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. The methods of the invention are suited for the treatment of cancers including lung cancer, breast cancer, bladder cancer, esophagus cancer, prostate cancer, cholangiocellular carcinoma and testicular seminoma.